FedOpsFedOps
Description
SOURCES SOUGHT NOTICE Proteomic Biomarker Testing Services Using CNS Panel 220 Argo NULISA Platform Notice Type: Sources Sought / Market Research Agency: Department of Health and Human Services (HHS), National Institutes of Health (NIH) Office: NIA/CARD Notice Number: SS-NIH-PCA-NIA-01589 PSC: Q301 – Medical Laboratory Testing NAICS: 541380 – Testing Laboratories and Services Response Due Date: May 13, 2026 11:00am EST DISCLAIMER This is a Sources Sought Notice issued solely for information and planning purposes and does not constitute a solicitation. This notice is issued in accordance with FAR Part 10, Market Research. This is not a Request for Proposal (RFP), Request for Quotation (RFQ), or Invitation for Bid (IFB), and it does not obligate the Government to award a contract or otherwise pay for the information submitted. The purpose of this notice is to identify qualified and interested sources capable of meeting the Government's requirement and to assist the Government in determining the appropriate acquisition strategy, including whether a set-aside is feasible. Responses to this notice are voluntary. The Government will not reimburse any costs incurred in preparing or submitting a response. Any information received may be used by the Government for planning purposes only. 1. TITLE Proteomic Biomarker Testing Services for Alzheimer's Disease and Related Dementias Research Using the CNS Panel 220 Argo NULISA Platform 2. INTRODUCTION The National Institutes of Health (NIH), Intramural Center for Alzheimer's Disease and Related Dementias, is conducting market research to determine the availability and capability of qualified contractors to provide proteomic biomarker testing services using the CNS panel 220 Argo NULISA platform for Government-furnished biospecimens. The Government seeks sources capable of performing high-throughput, quality-controlled proteomic testing and providing associated data files, quality control documentation, and harmonization-related reporting to support Alzheimer's disease and related dementias (AD/ADRD) research. 3. BACKGROUND The NIH Intramural Center for Alzheimer's Disease and Related Dementias is an interdisciplinary initiative dedicated to advancing the understanding, diagnosis, and treatment of Alzheimer's disease and related dementias. Biomarkers are critical for understanding disease mechanisms, supporting diagnosis, and monitoring disease progression and therapeutic efficacy. NIH requires standardized, high-throughput proteomic analysis to support these objectives. The Government intends to furnish biospecimens from well-characterized patient cohorts for testing using the CNS panel 220 Argo NULISA platform. Resulting data will be used to identify biomarkers associated with underlying molecular changes in AD/ADRD and to support cross-cohort harmonization and downstream scientific analysis. 4. OBJECTIVE The objective of this requirement is to obtain high-quality proteomic biomarker data from Gove…
Classification
Place of Performance
Contracting Office
Contacts
Attachments (2)